RecruitingPhase 3NCT04161053

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Sponsor

Tanta University

Enrollment

60 participants

Start Date

Nov 1, 2018

Study Type

INTERVENTIONAL

Conditions

Hepatic Encephalopathy

Summary

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Eligibility

Min Age: 20 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nitazoxanide and a drug called Rifaximin for people with hepatic encephalopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.